The company reported ₤50.5 million for the year ended Sept. 30, 2012, up just slightly from the ₤49.7 million reported for the previous year. The company includes an Invibio biomaterial solutions business line.
More Articles on Orthopedic Devices:
13 Spine Devices Receive FDA 510(k) Clearance in September
How A Facility Implements Generic Orthopedic Implants
Pinnacle Spine Group Wins FDA Approval for Direct Lateral System
